• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Nov. 6, 2014

View Archived Issues

Medical device tax repeal still a key issue

One of the issues that will rise again to the surface as the 114th Congress convenes is tax reform; the medical device tax is back in play as well. One big question is whether these will be handled separately, but one line of thinking is that the pressure to find offsets for the device tax may force the House and Senate to package any repeal legislation into a larger bill in order to address the pay-for question. Read More

One IPO exits, another files as biotechs weigh year-end pricings

Another biotech squeaked through the initial public offering (IPO) door Wednesday, as Xenon Pharmaceuticals Inc. priced 4 million shares at $9 to raise a smallish $36 million. But the IPO queue remained at three dozen companies after Inotek Pharmaceuticals Corp. entered as fast as Xenon could exit. The Lexington, Mass.-based biotech, which is developing a small molecule eye drop therapy to treat glaucoma, is seeking to raise up to $86 million, including overallotments, and plans to offer another $46 million in five-year convertible debt concurrent with the IPO. Read More

DKFZ looks to Oryx for path through translation thicket

FRANKFURT – With a maturing clinical pipeline and big ambitions for creating a new paradigm for translational research in Germany, Oryx GmbH & Co. KG, a company that has flown under the radar since its formation, finally set out its stall at Bio-Europe. Read More

Medicines' carbapenem combo ready to TANGO in pivotal trials in CRE

Amid the rising rate of multidrug-resistant infections, The Medicines Co. launched a pivotal program testing Carbavance, a combination anti-infective, against carbapenem-resistant Enterobacteriaceae (CRE), which the Centers for Disease Control and Prevention has called one of the most deadly gram-negative pathogens. Read More

Vaccine may be on the horizon for hepatitis C

The treatment of hepatitis C has undergone profound shifts for the better in recent years with the advent of first targeted therapies and then all-oral regimens. Read More

Karolinska benefits from unprecedented $128M investment by Thai firm

LONDON – One of Europe's leading medical institutes, the Karolinska in Sweden, has secured $128 million for its spin-out companies from Thailand's Charoen Pokphand Group (CP Group), in an unprecedented investment by an Asian company in European university technology. Read More

Other news to note

Micreos BV, of Wageningen, The Netherlands, said it has developed Staphefekt, a bacteria-killing enzyme, or endolysin, specific to Staphylococcus aureus, which is equally effective in killing methicillin-resistant S. aureus. This is the first endolysin available for human use on intact skin. Read More

Pharma: Other news to note

Ranbaxy Laboratories Ltd., of Mumbai, India, said it received FDA approval to manufacture and market Fenofibrate capsules USP, 43 mg and 130 mg indicated for primary hypercholesterolemia, mixed dyslipidemia and severe hypertriglyceridemia. The FDA's Office of Generic Drugs has determined the formulations to be bioequivalent and have the same therapeutic effect as that of the reference listed drug Antara capsules, 43 and 130 mg, respectively, of Lupin Atlantis. Read More

In the clinic

Biolinerx Ltd., of Jerusalem, reported final results from the phase I/II study of BL-7010, showing the co-polymer, designed to treat celiac disease, was safe and well-tolerated in single- and repeated-dose administrations. Pharmacokinetic analyses across all cohorts revealed no systemic exposure of BL-7010 in plasma and urine samples. The study also enabled the company to determine the optimal safe dose of 1 gm, three times daily, for future development. Read More

Financings

Tolero Pharmaceuticals Inc. closed the second tranche of its series B financing, bringing its total amount raised to $22.4 million. Fred Alger Management Inc. led the round, with investments from other institutional and individual investors. Read More

Earnings

Corcept Therapeutics Inc., of Menlo Park, Calif., said it recognized $7.3 million in net revenue for the third quarter of 2014 compared to $5.9 million in the second quarter. Revenue increased 177 percent over the prior year comparable period on continued uptake of Korlym for the treatment of Cushing's syndrome. Read More

Stock movers

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 26, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 26, 2025.
  • Deal handshake with coin, chart background

    After axing 95% workforce, Vor bets $4B+ on Remegen’s telitacicept

    BioWorld
    Just a month after laying off 147 employees and announcing plans to mull “strategic alternatives,” Vor Biopharma Inc. reported raising $175 million in private...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 24, 2025
  • Lei Qian, clinical vice president, Innovent

    Innovent raises HKD$4.3B to advance R&D pipeline, global expansion

    BioWorld
    Innovent Biologics Inc. announced a HKD$4.3 billion (US$547 million) placement on the Hong Kong Stock Exchange to advance its R&D projects and to fund its global...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe